3 not yet recruiting, 3 recruiting, 1 terminated. 3 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Terminated 1 |
| Phase 2 | 2 | Not yet recruiting 2 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow HR+ Breast Cancer: new trials by email Literature Review of HR+ Breast Cancer trials Research Report on HR+ Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors SHY-ONC6 - Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | SHY Therapeutics | 30 | 2026-06-24 | 2026-10-22 |
| SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study SHR- A1811 - SHR-A1811, HER2-Postive Breast Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2025-12-20 | 2025-12-29 |
| Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer CBD oil, Placebo - Breast Cancer Stage I, Breast Cancer Stage II | Phase 3 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 130 | 2025-12-01 | 2025-12-02 |
| SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers SC-101 - TNBC - Triple-Negative Breast Cancer, HR+ Breast Cancer | Phase 2 | Not yet recruiting | Tianjin ConjuStar Biologics Co., Ltd. | 120 | 2025-09-20 | 2025-09-11 |
| A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole - HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | NiKang Therapeutics, Inc. | 361 | 2025-03-25 | 2026-08-28 |
| Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) . Anlotinib+eribulin/nab-paclitaxel/etoposide/capecitabine/pembrolizumab/ sintilimab/ fulvestrant, etc - HR+ Breast Cancer | Recruiting | Hunan Cancer Hospital | 80 | 2024-12-05 | 2024-12-16 | |
| (VELA) Study of BLU-222 in Advanced Solid Tumors BLU-222, Carboplatin, Ribociclib - Advanced Solid Tumors, HR+ Breast Cancer | Phase 1 | Terminated | Blueprint Medicines Corporation | 50 | 2022-04-07 | 2025-11-28 |
Breast Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Stomach Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinosarcoma (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Sarcoma (1)
Neoplasms (6) · Neoplasms by Site (6) · Breast Diseases (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Breast Neoplasms (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Connective and Soft Tissue (2) · Stomach Diseases (2) · Adenoma (1) · Adnexal Diseases (1)
Fulvestrant (3) · Carboplatin (1) · Letrozole (1) · dalpiciclib (1) · pyrotinib (1) · ribociclib (1) · sintilimab (1)
Blueprint Medicines Corporation (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hunan Cancer Hospital (1) · NiKang Therapeutics, Inc. (1) · SHY Therapeutics (1) · Tianjin ConjuStar Biologics Co., Ltd. (1) · Tianjin Medical University Cancer Institute and Hospital (1)
United States (3) · China (1) · France (1) · Italy (1) · United Kingdom (1)
2023 (1)